Analysis of rare mutations in non-small cell lung cancer patients
Molecular Landscape Analysis and Clinical and Therapeutic Implications for NSCLC Patients With Rare Mutations
This study looks at rare genetic changes in people with non-small cell lung cancer to see if understanding these changes can lead to better treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Locations | 2 sites (Shanghai, Shanghai Municipality and 1 other locations) |
| Trial ID | NCT05701787 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with non-small cell lung cancer (NSCLC) who have rare mutations. It aims to analyze the molecular landscape of these mutations and their clinical implications, utilizing next-generation sequencing (NGS) to identify potential targeted therapies. By understanding the diverse mutations present in NSCLC, the study seeks to address the unmet need for effective treatment options tailored to these specific genetic profiles. The findings could help improve treatment strategies and patient outcomes in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed NSCLC and specific rare mutations.
Not a fit: Patients without rare mutations in NSCLC or those under 18 years of age may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective targeted therapies for NSCLC patients with rare mutations, improving their quality of life and survival rates.
How similar studies have performed: Other studies have shown success in targeting specific mutations in NSCLC, indicating that this approach has potential for meaningful advancements in treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven diagnosis of NSCLC with rare mutations including EGFR rare mutations, ALK fusion, ROS1 fusion, BRAF V600E, cMET exon 14 skipping, KRAS G12C, RET fusion, NTRK fusion, etc. * 18 years of age or older * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * None
Where this trial is running
Shanghai, Shanghai Municipality and 1 other locations
- Xiaomin Niu — Shanghai, Shanghai Municipality, China (Recruiting)
- Xiaomin Niu — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Xiaomin Niu — Shanghai Chest Hospital
- Study coordinator: Xiaomin Niu
- Email: ar_tey@hotmail.com
- Phone: 021-22200000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.